Ibotenic acid




































































Ibotenic acid

Ibotenic acid2.png

Ibotenic acid 3D structure.png
Names

IUPAC name
(S)-2-Amino-2-(3-hydroxyisoxazol-5-yl)acetic acid

Other names
Ibotenic acid

Identifiers

CAS Number

  • 2552-55-8 ☒N

3D model (JSmol)
  • Interactive image

ChEMBL


  • ChEMBL284895 ☑Y


  • ChEMBL30285 ☑Y

ChemSpider

  • 1196 ☑Y

ECHA InfoCard
100.151.170

IUPHAR/BPS
  • 1371


PubChem CID
  • 1233




Properties

Chemical formula
C5H6N2O4

Molar mass
7002158113000000000♠158.113 g·mol−1

Melting point
 151-152 °C (anhydrous)
144-146 °C (monohydrate)

Solubility in water

 H2O: 1 mg/mL
0.1 M NaOH: 10.7 mg/mL
0.1 M HCl: 4.7 mg/mL

Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).


☒N verify (what is ☑Y☒N ?)

Infobox references

Ibotenic acid or (S)-2-amino-2-(3-hydroxyisoxazol-5-yl)acetic acid, also referred to as ibotenate, is a chemical compound and psychoactive drug which occurs naturally in Amanita muscaria and related species of mushrooms typically found in the temperate and boreal regions of the northern hemisphere. It is a conformationally-restricted analogue of the neurotransmitter glutamate, and due to its structural similarity to this neurotransmitter, acts as a non-selective glutamate receptor agonist.[1] Because of this, ibotenic acid can be a powerful neurotoxin, and is employed as a "brain-lesioning agent" through cranial injections in scientific research.[2][3]




Contents






  • 1 Pharmacology


  • 2 Biological properties


    • 2.1 Mechanism of action


    • 2.2 Biological effects


    • 2.3 Treatment




  • 3 Use in research


  • 4 See also


  • 5 References





Pharmacology





Amanita muscaria, which contains ibotenic acid


Ibotenic acid acts as a potent agonist of the NMDA and group I (mGluR1 and mGluR5) and II (mGluR2 and mGluR3) metabotropic glutamate receptors.[1][4] It is inactive at group III mGluRs.[5] Ibotenic acid also acts as a weak agonist of the AMPA and kainate receptors.[1][4] In addition, due to in vivo decarboxylation into muscimol, it acts indirectly as a potent GABAA and GABAA-ρ receptor agonist.[4] Unlike muscimol, the principal psychoactive constituent of Amanita muscaria that is understood to cause sedation and delirium, ibotenic acid's psychoactive effects are not known independent of its serving as a prodrug to muscimol, however it may be speculated that it would act as a stimulant.[6][7]




Biological properties



Mechanism of action


Ibotenic acid is an agonist of glutamate receptors, specifically at both the N-methyl-D-aspartate, or NMDA and trans-ACPD receptor sites in a multiple of systems in the central nervous system. Ibotenic neurotoxicity can be enhanced by glycine and blocked by dizocilpine. Dizocilpine acts as an uncompetitive antagonist at NMDA receptors.[8]


Ibotenic acid toxicity comes from activation of the NMDA receptors. NMDA receptors are related to synaptic plasticity and work with metabotropic glutamate receptors to establish long term potentiation or LTP. The process of long term potentiation is believed to be related to the acquisition of information. The NMDA receptor functions properly by allowing Ca2+ ions to pass through after activation at the receptor site.




Activated NMDAR


The binding of ibotenic acid allows excess Ca2+ into the system which results in neuronal cell death. Ca2+ also activates CaM-KII or Ca2+/Calmodulin Kinase which phosphorylates multiple enzymes. The activated enzymes then begin producing reactive oxygen species which damages surrounding tissue. The excess Ca2+ results in the enhancement of the mitochondrial electron transport system which will further increase the number of reactive oxygen species.[9]



Biological effects


Ibotenic acid typically affects NMDA and trans-ACPD receptors in the central nervous system.[8] Due to their targeting of these systems the symptoms associated with Ibotenic acid poisoning are often related to perception and control.


Most of ingested ibotenic acid is probably decarboxylated into muscimol so the effects of ingesting ibotenic acid are similar to muscimol's effects.[10] Symptoms associated with ibotenic acid are usually onset within 30–60 minutes and include a range of nervous system effects. The most common symptoms include, nausea, vomiting, and drowsiness. However, after the first hour symptoms begin to include confusion, euphoria, visual and auditory distortions, sensations of floating, and retrograde amnesia.[11]


Symptoms are slightly different for children, typically beginning after 30–180 minutes. Dominant symptoms in children include ataxia, obtundation, and lethargy. Seizures are occasionally reported, however, more commonly with children.[11]



Treatment





Lorazepam, a benzodiazepine





Atropine


Treatment of ibotenic acid poisoning is limited and varies as the toxic dose of the compound varies from person to person. Patients admitted to the hospital for ibotenic acid poisoning are typically given charcoal in order to stop the absorption of the compound and prevent further intoxication. Upon receiving charcoal treatment the patient’s vital signs are monitored and toxicity usually lasts between 6 and 8 hours; however, some symptoms may take up to a few days to subside. Occasionally, to reduce the discomfort associated with symptoms, benzodiazepines will be administered to control panic attacks and hallucinations.


Special attention should be given to monitoring breathing, airway control, and circulation. If treatment occurs within the first hour of ingestion gastric lavage may be effective. If vomiting becomes too intense intravenous fluids are administered, psychiatric care may also be provided.


In rare cases anticholinergic drugs, such as atropine, may be needed.[12]



Use in research


Ibotenic acid used for the lesioning of rat's brains is kept frozen in a phosphate-buffered saline solution at a pH of 7.4, and can be kept for up to a year with no loss in toxicity. Injection of .05-.1 microliters of Ibotenic acid into the hippocampus at a rate of .1 microliter/min resulted in semi-selective lesioning. Hippocampal lesioning led to a considerable loss of cells in pyramidal cells (CA1-CA3) as well as granule cells in the dentate gyrus. Ibotenic acid lesioning also causes some damage to axons along the perforant pathway.


Typically when lesioning is done with other chemicals the subject can not relearn a task. However, due to Ibotenic acid's reactivity with glutamate receptors such as the NMDA receptor, Ibotenic acid lesioning does allow the subject to relearn tasks. Ibotenic acid lesioning is thus preferred in studies where re-learning a task after lesioning is essential. Compared to other lesioning agents, Ibotenic acid is one of the most site-specific; however, less-damaging alternatives are presently sought.[13]



See also


  • Quisqualic acid


References





  1. ^ abc Tommy Liljefors; Povl Krogsgaard-Larsen; Ulf Madsen (25 July 2002). Textbook of Drug Design and Discovery, Third Edition. CRC Press. pp. 263–. ISBN 978-0-415-28288-8..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"""""""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ Becker, A; Grecksch, G; Bernstein, HG; Höllt, V; Bogerts, B (1999). "Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis". Psychopharmacology. 144 (4): 333–8. doi:10.1007/s002130051015. PMID 10435405.


  3. ^ Isacson, O; Brundin, P; Kelly, PA; Gage, FH; Björklund, A (1984). "Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum". Nature. 311 (5985): 458–60. Bibcode:1984Natur.311..458I. doi:10.1038/311458a0. PMID 6482962.


  4. ^ abc Wantanabe (23 July 1999). Pharmacological Research on Traditional Herbal Medicines. CRC Press. pp. 107–. ISBN 978-90-5702-054-4.


  5. ^ Hermit MB, Greenwood JR, Nielsen B, Bunch L, Jørgensen CG, Vestergaard HT, Stensbøl TB, Sanchez C, Krogsgaard-Larsen P, Madsen U, Bräuner-Osborne H (2004). "Ibotenic acid and thioibotenic acid: a remarkable difference in activity at group III metabotropic glutamate receptors". Eur. J. Pharmacol. 486 (3): 241–50. doi:10.1016/j.ejphar.2003.12.033. PMID 14985045.


  6. ^ Chilton 1975; Theobald et al. 1968


  7. ^ Chilton 1975; Ott 1976a


  8. ^ ab Zinkand, William; Moore, W.; Thompson, Carolann; Salama, Andre; Patel, Jitendra (February 1992). "Ibotenic acid mediates neurotoxicity and phosphoinositide hydrolysis by independent receptor mechanisms". Molecular and Chemical Neuropathology. 16 (1–2): 1–10. doi:10.1007/bf03159956. PMID 1325800.


  9. ^ Sureda, F. "Excitotoxicity and the NMDA receptor". eurosiva. Retrieved 30 April 2015.


  10. ^ Michelot, Didier; Melendez-Howell, Leda Maria (2003). "Amanita muscaria: chemistry, biology, toxicology, and ethnomycology" (PDF). Mycological Research. 107 (2): 131–146. doi:10.1017/s0953756203007305. PMID 12747324.


  11. ^ ab Duffy, Thomas. "Symptoms of ibotenic/muscimol poisoning (isoxazol poisoning)". Toxic Fungi of Western North America. MykoWeb. Retrieved 30 April 2015.


  12. ^ Rolston-Cregler, Louis. "Hallucinogenic Mushroom Toxicity". MedScape. Retrieved 30 April 2015.


  13. ^ Jarrard, Leonard (2 February 1989). "On the use of ibotenic acid to lesion selectively different components of the hippocampal formation" (PDF). Journal of Neuroscience Methods. 29 (3): 251–259. doi:10.1016/0165-0270(89)90149-0. Retrieved 29 April 2015.















Comments

Post a Comment

Popular posts from this blog

Information security

Image
This article is part of a series on Information security Related security categories Internet security Cyberwarfare Computer security Mobile security Network security Threats Computer crime Vulnerability Eavesdropping Malware Spyware Ransomware Trojans Viruses Worms Rootkits Bootkits Keyloggers Screen scrapers Exploits Backdoors Logic bombs Payloads Denial of service Defenses Computer access control Application security Antivirus software Secure coding Secure by default Secure by design Secure operating systems Authentication Multi-factor authentication Authorization Data-centric security Encryption Firewall Intrusion detection system Mobile secure gateway Runtime application self-protection (RASP) v t e Information security , sometimes shortened to InfoSec , is the practice of preventing unauthorized access, use, disclosure, disruption, modification, inspection, recording or destruction of information. Th...
Read more

Lambak Kiri

Image
For Lambak Kiri public housing area, see Lambak Kiri Landless Indigenous Citizens' Housing Scheme. Village in Brunei-Muara, Brunei Lambak Kiri Village Location in Brunei Coordinates: 4°59′26″N 114°57′04″E  /  4.990472°N 114.951114°E  / 4.990472; 114.951114 Coordinates: 4°59′26″N 114°57′04″E  /  4.990472°N 114.951114°E  / 4.990472; 114.951114 Country Brunei District Brunei-Muara Mukim Berakas A Government  • Village head Hamdani Omar Postcode BB1214 Lambak Kiri is a populated place in Brunei-Muara District, Brunei. It is officially a village subdivision under Berakas A, a mukim in the district. Lambak Kiri may also refer to the greater area which includes the Lambak Kiri public housing area of the Landless Indigenous Citizens' Housing Scheme (Malay: Skim Tanah Kurnia Rakyat Jati ), although the latter is a separate subdivision. Contents 1 Name 2 Administration 3 See also 4 References Name ...
Read more

章鱼与海女图

Image
本条目 可参照英語維基百科相應條目来扩充 。 （2014/5/25） 若您熟悉来源语言和主题，请协助参考外语维基扩充条目。请勿直接提交机械翻译，也不要翻译不可靠、低品质内容。依版权协议，译文需在编辑摘要注明来源，或于讨论页顶部标记 {{Translated page}} 标签。 本条目 需要擴充。 （2013年8月15日） 请協助改善这篇條目，更進一步的信息可能會在討論頁或扩充请求中找到。请在擴充條目後將此模板移除。 《 章鱼与海女 》（日语： 蛸と海女 ／ たことあま   Tako to ama ）是一幅由日本畫家葛饰北斋创作的浮世绘，出自1814年（文化4年）出版的艳本《喜能会之故真通》（日语： 喜能会之故真通 ／ きのえのこまつ   Kinoe no Komatsu ）。畫中有兩隻章鱼以觸手攻擊一名採珠的海女，並進行擬似戀獸癖的交媾行為。作品尺寸为6½" × 8¾" （16.51 cm × 22.23 cm）。 [1] 在此之前的类似作品还有北尾重政的艳本《謡曲色番組》及勝川春潮的艳本《艳本千夜多女志》等，有被北斋作为参考的可能性。 《章鱼与海女图》有不同英文翻译，一般称The Dream of the Fisherman's Wife，又作Girl Diver and Octopi、Diver and Two Octopi，Richard Douglas Lane称其为 Girl Diver and Octopi [2] ，Mathi Forrer 称其为 Pearl Diver and Two Octopi [3] ，Danielle Talerico 称其为 Diver and Two Octopi 。 [4] 目录 1 作品介绍 1.1 画中对话 1.2 解释 2 评价 3 影响 3.1 模仿作品 4 另见 5 参考来源 6 外部連結 作品介绍 画中对话 原文 译文 大蛸： いつぞハいつぞハとねらいすましてゐたかいがあつて、けふといふけふ、とうとうとらまへたア。てもむつくりとしたいいぼぼだ。いもよりハなをこうぶつだ。サアサア、すつてすつてすいつくして...
Read more